Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis (NCT05809414) | Clinical Trial Compass
UnknownPhase 3
Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis
Spain144 participantsStarted 2022-11-28
Plain-language summary
Multiple Sclerosis (MS) is the most frequent cause of non-traumatic disability in people under 55 years of age. Fatigue is the most frequent and disabling symptom in the disease, and for which there is no effective treatment. Among the proposed drugs, amantadine is the one that could be most useful, although up to now it has not been adequately demonstrated due to a lack of sufficiently powerful and methodologically appropriate clinical trials. Transcranial magnetic stimulation (TMS) has recently been proposed as a useful treatment for fatigue in MS in preliminary studies.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Expanded Disability Status Scale mark 1.5 - 4.5
✓. Fatigue Severity Scale \> 4
✓. Beck Depression Inventory \< 30
✓. No relapse for, at least, three month prior to screening
✓. Drug washout period = 4 weeks for any fatigue aimed drug
✓. Patient capable to sign the informed consent
Exclusion criteria
✕. Fatigue causing disease other than multiple sclerosis:
✕. sleep apnea
✕. other autoimmune disease that could be explain the fatigue.
✕. endocrine autoimmune disease if the blood test is not in range in the last 6 month.